Gujarat Themis Biosyn
BSE: 506879 | NSE: | ISIN: INE942C01045 | SECTOR: Biotechnology & DrugsOpen
405.00High
412.95Low
402.00Prev Close
404.70P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
29.73BVolume
37.78KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
409.10Ask
409.20
Promoter Pledge Holding - 2.34%
Promoter Name | No of Shares | Percentage |
---|---|---|
Pharmaceutical Business Group (India) Ltd | 17,00,000 | 2.34% |
Company Description
- Biotechnology & Drugs
BSE
506879NSE
ISIN
INE942C01045
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
Company Officers
Tapas Thakurata
Chief Executive OfficerBharat Desai
Chief Financial OfficerRahul Soni
Compliance Officer, Company Secretary